Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 32

Sort by

Sort Order Select

Journal Articles

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Cédric Rossi, MD PhD, Marc André, Clémentine Joubert, PhD, Catherine Fortpied, Pauline Brice, Bénédicte Deau-Fisher, MD, Herve Ghesquieres, MD PhD, Luc Mathieu Fornecker, MD PhD, Anne-Claire Gac, MD, Julien Lazarovici, Aspasia Stamatoullas, MD, John Raemakers, Massimo Federico, MD, Marie Maerevoet, MD, Sarah Bailly, MD, Salim Kanoun, MD, Michel Meignan, Anne Ségolène Cottereau, Rene-Olivier Casasnovas, MD

Blood (2019) 134 (Supplement_1): 128.

https://doi.org/10.1182/blood-2019-125976

Published: 2019

Journal Articles

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Laurie H Sehn, MD, David W. Scott, MBChB, PhD, Diego Villa, MD FRCPC, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Pedro Farinha, MD PhD, Graham W Slack, MD PhD, Don Wilson, MD, R. Petter Tonseth, MD, Joseph M. Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 401.

https://doi.org/10.1182/blood-2019-128722

Published: 2019

Journal Articles

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Charles Macaulay, MSc, BA, Stefan Alig, MD, David M. Kurtz, MD PhD, Michael C. Jin, BS, Stephen Opat, Joanne Soo, MD, Brian Sworder, MD PhD, Mark S. Hertzberg, MD PhD, Maher K. Gandhi, PhD, Maximilian Diehn, MD PhD, Ash A. Alizadeh, MD PhD

Blood (2019) 134 (Supplement_1): 1600.

https://doi.org/10.1182/blood-2019-131278

Published: 2019

Journal Articles

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Vania Phuoc, MD, Leidy Isenalumhe, MD, Hayder Saeed, MD, Celeste Bello, MD, Bijal Shah, MD, Lubomir Sokol, MD PhD, Julio Chavez

Blood (2019) 134 (Supplement_1): 2898.

https://doi.org/10.1182/blood-2019-122393

Published: 2019

Journal Articles

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Phoebe Tsz Man Cheng, BSc,MD, Diego Villa, MD MPH, R. Petter Tonseth, MD, David W. Scott, MBChB, PhD, Alina S Gerrie, MD MPH, Ciara L Freeman, MSc, MBBChir, Christina Aquino Parsons, MD, Tom Pickles, MD, Andrea Lo, MD, Don Wilson, MD, Brian Skinnider, MD, Laurie H Sehn, MD, Joseph M Connors, MD, Kerry J Savage, BSc, MD MSc

Blood (2019) 134 (Supplement_1): 2845.

https://doi.org/10.1182/blood-2019-122019

Published: 2019

Journal Articles

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Donald Berry, PhD, Kristine Broglio, MS, Carol Ward, MSc, Federico Mattiello, PhD, Deniz Sahin, BSc, Tina G Nielsen, MD PhD, Anna McGlothlin, PhD, Corrine Elliott, MS, Thomas E. Witzig, MD, Laurie H Sehn, MD, Marek Trněný, MD, Umberto Vitolo, Maurizio Martelli, MD, Lale Kostakoglu, MD MPH, Grzegorz Nowakowski, MD

Blood (2019) 134 (Supplement_1): 4101.

https://doi.org/10.1182/blood-2019-124067

Published: 2019

Journal Articles

Functional Properties of Hb S and Hb C in Stored Cpda-1 Red Blood Cells Concentrate — a Prospective Study

Susan Elisabeth Jorge, MMSc, PhD, Marcela Regina Grigoleto, BSc, Maria Lourdes Barjas Castro, MD PhD, Fernando F. Costa, MD, PhD, Maria de Fátima Sonati, MSc, PhD

Blood (2018) 132 (Supplement 1): 2548.

https://doi.org/10.1182/blood-2018-99-117298

Published: 2018

Journal Articles

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Blood (2017) 130 (11): 1315–1326.

https://doi.org/10.1182/blood-2017-02-766691

Published: 2017

Includes: Supplemental data

Journal Articles

Redesign of EAF Peg Hb As an Oxygen Transfer Catalyst for Improved Tissue Oxygenation of Hypoxic Areas: A Therapeutic for Anemia and Sickle Cell Disease

Savita Bhutoria, PhD, Amy Tsai, PhD, Marcos Intaglietta, PhD, Sandra M. Suzuka, MS, Sangeetha Thangaswamy, PhD, Prabhakaran Muthuchidambaram, PhD, Caterina Minniti, MD, Henny Heisler H Billett, MD, Craig A Branch, PhD, Seetharama A Acharya, PhD

Blood (2016) 128 (22): 4845.

https://doi.org/10.1182/blood.V128.22.4845.4845

Published: 2016

Journal Articles

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Pier Luigi Zinzani, MD PhD, Vincent Ribrag, MD, Craig H. Moskowitz, MD, Jean-Marie Michot, MD, John Kuruvilla, MD, Arun Balakumaran, MD PhD SM, Yayan Zhang, PhD, Patricia Marinello, PharmD, Sabine Chlosta, MD, Eric Gustafson, PhD, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2016) 128 (22): 619.

https://doi.org/10.1182/blood.V128.22.619.619

Published: 2016

Journal Articles

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Blood (2016) 128 (22): 184.

https://doi.org/10.1182/blood.V128.22.184.184

Published: 2016

Journal Articles

Early Treatment Intensification with R-ICE Chemotherapy Followed By Autologous Stem Cell Transplantation (ASCT) Using Zevalin-BEAM for Patients with Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) As Identified By Interim PET/CT Scan Performed after Four Cycles of R-CHOP-14: A Multicenter Phase II Study of the Australasian Leukaemia Lymphoma Study Group (ALLG)

Blood (2015) 126 (23): 815.

https://doi.org/10.1182/blood.V126.23.815.815

Published: 2015

Journal Articles

Predictive Value of Interim 18 f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study

He Huang, Jiatian Lin, Chengcheng Guo, Shanshan Li, MD, Huangming Hong, Xueying Li, Mengping Zhang, Zhongjun Xia, MD, Tongyu Lin

Blood (2015) 126 (23): 1458.

https://doi.org/10.1182/blood.V126.23.1458.1458

Published: 2015

Journal Articles

Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Salvage Chemotherapy and Intention to Transplant in the Rituximab Era

Santosha A. Vardhana, MD PhD, Craig H. Moskowitz, MD, Craig S. Sauter, MD, Matthew J Matasar, MD MS, Natasha Galasso, Kaitlin M Woo, MS, Zhigang Zhang, PhD

Blood (2015) 126 (23): 1986.

https://doi.org/10.1182/blood.V126.23.1986.1986

Published: 2015

Journal Articles

The Role of Interim F-18 FDG PET/CT in Patients of T Lymphoblastic Leukemia/Lymphoma Treated with ALL-Type Regimens

Liang Wang, MD, Zhongjun Xia, MD, Xiaoqin Chen, MD, Wen Long, MD

Blood (2015) 126 (23): 5015.

https://doi.org/10.1182/blood.V126.23.5015.5015

Published: 2015

Journal Articles

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Pier Luigi Zinzani, MD PhD, Vincent Ribrag, MD, Craig H. Moskowitz, MD, Jean-Marie Michot, John Kuruvilla, MD, Arun Balakumaran, MD PhD SM, Ellen Snyder, PhD, Patricia Marinello, PharmD, Margaret A. Shipp, MD, Philippe Armand, MD PhD

Blood (2015) 126 (23): 3986.

https://doi.org/10.1182/blood.V126.23.3986.3986

Published: 2015

Journal Articles

Predictive Value of Interim 18 f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study of Chinese Southwest Oncology Group (CSWOG)

He Huang, MD, Jia Tian Lin, Chengcheng Guo, Huangming Hong, MD, Raj Shrestha Prem, Xueying Li, Mengping Zhang, Shanshan Li, Xiaojie Fang, Zhao Wang, Zhongjun Xia, MD, Tongyu Lin, MD PhD

Blood (2014) 124 (21): 3011.

https://doi.org/10.1182/blood.V124.21.3011.3011

Published: 2014

Journal Articles

Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT

Julien Dubreuil, Roch Houot, MD PhD, Steven Le Gouill, Christiane Mounier, MD, Stéphane Courby, MD, Caroline Dartigeas, MD, Krimo Bouabdallah, MD, Marie Pierre Moles, MD, Alexis Magda, Olivier Tournilhac, MD, Mario Ojeda Uribe, Jean Cyril Bourre, Caroline Bodet-Milin, MD, Jean-Philippe Vuillez, MD PhD, Remy Gressin, MD

Blood (2014) 124 (21): 3070.

https://doi.org/10.1182/blood.V124.21.3070.3070

Published: 2014

Journal Articles

Prognostic Impact of Interim and Final PET in Primary Mediastinal Large B-Cell Lymphoma Treated with Intensive Etoposide-Based Therapy

Vít Procházka, MD, PhD, Lenka Henzlová, MD, Eva Buriánková, MD PhD, Zuzana Prouzová, MD, Ale Obr, MD, Martin Novák, Dr., Jiří Minařík, MD PhD, Karel Indrák, MD Prof., Tomá Papajík, MD PhD ass. prof.

Blood (2014) 124 (21): 1729.

https://doi.org/10.1182/blood.V124.21.1729.1729

Published: 2014

Journal Articles

Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL)

Jehan Dupuis, MD, Franck Morschhauser, MD PhD, Herve Ghesquieres, MD PhD, Herve Tilly, MD, Olivier Casasnovas, MD, Sandy Amorim, MD, Vincent Ribrag, MD, Bertrand Coiffier, MD PhD

Blood (2014) 124 (21): 504.

https://doi.org/10.1182/blood.V124.21.504.504

Published: 2014

NARROW

Stage IIb High Risk Hodgkin Lymphoma Treated in the H10 and AHL2011 Trials: Similar Efficacy of Both Strategies and Prognostic Impact of Baseline Tmtv and PET2 Response

Long-Term Follow-up of a PET-Guided Approach to Treatment of Limited-Stage Diffuse Large B-Cell Lymphoma (DLBCL) in British Columbia (BC)

Interim Circulating Tumor DNA As a Prognostic Biomarker in the Setting of Interim PET-Based Adaptive Therapy for DLBCL

Impact of Interim FDG-PET (iPET) in the Outcomes of Patients with Aggressive B-Cell Lymphomas Receiving DA-EPOCH-R

Outcome of Limited Stage Nodular Lymphocyte Predominant Hodgkin Lymphoma (NLPHL) and Evaluation of a PET-Adapted Approach

Patient-Level Meta-Analysis of End-of-Therapy PET-CR as a Surrogate Endpoint for PFS and OS in Patients with Previously Untreated DLBCL: Implications for Clinical Trial Design

Functional Properties of Hb S and Hb C in Stored Cpda-1 Red Blood Cells Concentrate — a Prospective Study

FDG-PET–driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study

Redesign of EAF Peg Hb As an Oxygen Transfer Catalyst for Improved Tissue Oxygenation of Hypoxic Areas: A Therapeutic for Anemia and Sickle Cell Disease

Phase 1b Study of Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Results from the Ongoing Keynote-013 Trial

Prognostic Value of Baseline Quantitative PET Metrics for Patients with Unfavourable Early Stage Hodgkin Lymphoma Enrolled in the Standard Arm of the EORTC/Lysa/FIL H10 Trial

Predictive Value of Interim 18 f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study

Outcomes of Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Treated with Salvage Chemotherapy and Intention to Transplant in the Rituximab Era

The Role of Interim F-18 FDG PET/CT in Patients of T Lymphoblastic Leukemia/Lymphoma Treated with ALL-Type Regimens

Phase 1b Study of PD-1 Blockade with Pembrolizumab in Patients with Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL)

Predictive Value of Interim 18 f-FDG PET-CT Scans on Diffuse Large B-Cell Lymphoma Treated with R-CHOP: A Prospective Study of Chinese Southwest Oncology Group (CSWOG)

Long Term Results of a Multicenter Prospective Trial By the Lysa Group Evaluating the RiPAD+C Regimen (Combination of Rituximab, Bortezomib, Doxorubicin, Dexamethasone and Chlorambucil) As First-Line Therapy for Elderly Mantle Cell Lymphoma Patients (MCL): Prognostic Value of FDG-PET/CT

Prognostic Impact of Interim and Final PET in Primary Mediastinal Large B-Cell Lymphoma Treated with Intensive Etoposide-Based Therapy

Final Analysis of the RO-CHOP Phase Ib/II Study: Romidepsin in Association with CHOP in Patients with Peripheral T-Cell Lymphoma (PTCL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only